Abstract:Classical laboratory strains show limited genetic diversity and do not harness natural genetic variation. Mouse models relevant to Alzheimer's disease (AD) have largely been developed using these classical laboratory strains, such as C57BL/6J (B6), and this has likely contributed to the failure of translation of findings from mice to the clinic. Therefore, here we test the potential for natural genetic variation to enhance the translatability of AD mouse models. Two widely used AD-relevant transgenes, APPswe and PS1de9 (APP/PS1), were backcrossed from B6 to three wild-derived strains CAST/EiJ, WSB/EiJ, PWK/PhJ, representative of three Mus musculus subspecies. These new AD strains were characterized using metabolic, functional, neuropathological and transcriptional assays. Strain-, sex- and genotype-specific differences were observed in cognitive ability, neurodegeneration, plaque load, cerebrovascular health and cerebral amyloid angiopathy. Analyses of brain transcriptional data showed strain was the greatest driver of variation. We identified significant variation in myeloid cell numbers in wild type mice of different strains as well as significant differences in plaque-associated myeloid responses in APP/PS1 mice between the strains. Collectively, these data support the use of wild-derived strains to better model the complexity of human AD.Despite the rise in incidence of Alzheimer's disease (AD), it has been over a decade since a new drug treatment has been introduced. Recently, a number of pharmaceutical giants have shut down their AD research units. One issue that these companies and researchers have struggled with is the lack of translatability of preclinical studies to the clinic. One aspect that has come under heavy scrutiny is whether the mouse can be an appropriate model for a complex human disease such as AD. Current mouse models of AD have incorporated well-known early onset AD mutations on a single genetic background, C57BL/6J, which does not develop all features of human AD- namely marked neurodegeneration. Here we sought to improve the utility and translatability of mouse models through the use of three genetically distinct, wild-derived inbred mouse strains, CAST/EiJ, WSB/EiJ and PWK/PhJ. These mice encompass millions of genetic differences that have never before been explored in the context of modeling AD. Wild-derived mice that carried the early onset AD mutations exhibited robust differences in immune response to amyloid, evidence of mixed pathology and early neurodegeneration, better recapitulating what happens in human AD than previous models.

Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology.

Single-cell Spatial Transcriptomics Analysis of Alzheimer's Disease Pathogenesis in Mouse Models

Data from single nuclei RNA‐sequencing reveals a prodromal gene network response in excitatory neurons of a humanized rat Alzheimer’s disease model

Human Alzheimer's disease gene expression signatures and immune profile in APP mouse models: a discrete transcriptomic view of Aβ plaque pathology

Transcriptome and proteome profiling reveals TREM2-dependent and -independent glial response and metabolic perturbation in an Alzheimer's mouse model

Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease

TREM2-independent oligodendrocyte, astrocyte, and T cell responses to tau and amyloid pathology in mouse models of Alzheimer disease

Single cell transcriptome analysis of the THY-Tau22 mouse model of Alzheimer's disease reveals sex-dependent dysregulations

Single-cell spatial transcriptomics reveals distinct patterns of dysregulation in non-neuronal and neuronal cells induced by the Trem2R47H Alzheimer's risk gene mutation

Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease

Long-read transcriptomic identification of synaptic adaptation to amyloid pathology in the App(NL-G-F) knock-in mouse model of the earliest phase of Alzheimer's disease

Amyloid Accumulation Drives Proteome-wide Alterations in Mouse Models of Alzheimer's Disease-like Pathology

Integrated spatial and single‐cell transcriptomic analysis of genetic and sporadic forms of Alzheimer’s disease

Mitochondrial Molecular Abnormalities Revealed by Proteomic Analysis of Hippocampal Organelles of Mice Triple Transgenic for Alzheimer Disease.

Updates on mouse models of Alzheimer's disease

Sex- and region-specific cortical and hippocampal whole genome transcriptome profiles from control and APP/PS1 Alzheimer's disease mice

In-Depth Proteomic Analysis of De Novo Proteome in a Mouse Model of Alzheimer’s Disease

Enhancing face validity of mouse models of Alzheimer’s disease with natural genetic variation

Transcriptomic Profiling Reveals Neuroinflammation in the Corpus Callosum of a Transgenic Mouse Model of Alzheimer's Disease

Characterization of Alzheimer’s Disease-Associated Excitatory Neurons via Single-Cell RNA Sequencing Analysis

Proteomic Analysis of Protein Expression Throughout Disease Progression in a Mouse Model of Alzheimer’s Disease